PortalPublikationenEuroGuiDerm Guideline on the systemic treatment of Psoriasis...

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations

Standard

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. / Nast, A; Smith, C; Spuls, P I; Avila Valle, G; Bata-Csörgö, Z; Boonen, H; De Jong, E; Garcia-Doval, I; Gisondi, P; Kaur-Knudsen, D; Mahil, S; Mälkönen, T; Maul, J T; Mburu, S; Mrowietz, U; Reich, K; Remenyik, E; Rønholt, K M; Sator, P G; Schmitt-Egenolf, M; Sikora, M; Strömer, K; Sundnes, O; Trigos, D; Van Der Kraaij, G; Yawalkar, N; Dressler, C.

in: J EUR ACAD DERMATOL, Jahrgang 35, Nr. 2, 02.2021, S. 281-317.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Nast, A, Smith, C, Spuls, PI, Avila Valle, G, Bata-Csörgö, Z, Boonen, H, De Jong, E, Garcia-Doval, I, Gisondi, P, Kaur-Knudsen, D, Mahil, S, Mälkönen, T, Maul, JT, Mburu, S, Mrowietz, U, Reich, K, Remenyik, E, Rønholt, KM, Sator, PG, Schmitt-Egenolf, M, Sikora, M, Strömer, K, Sundnes, O, Trigos, D, Van Der Kraaij, G, Yawalkar, N & Dressler, C 2021, 'EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations', J EUR ACAD DERMATOL, Jg. 35, Nr. 2, S. 281-317. https://doi.org/10.1111/jdv.16926

APA

Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., De Jong, E., Garcia-Doval, I., Gisondi, P., Kaur-Knudsen, D., Mahil, S., Mälkönen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Rønholt, K. M., Sator, P. G., ... Dressler, C. (2021). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J EUR ACAD DERMATOL, 35(2), 281-317. https://doi.org/10.1111/jdv.16926

Vancouver

Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J EUR ACAD DERMATOL. 2021 Feb;35(2):281-317. https://doi.org/10.1111/jdv.16926

Bibtex

@article{ff87b07bf8514c67b4a65314d74bc2d4,
title = "EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations",
abstract = "This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.",
keywords = "Humans, Psoriasis/complications",
author = "A Nast and C Smith and Spuls, {P I} and {Avila Valle}, G and Z Bata-Cs{\"o}rg{\"o} and H Boonen and {De Jong}, E and I Garcia-Doval and P Gisondi and D Kaur-Knudsen and S Mahil and T M{\"a}lk{\"o}nen and Maul, {J T} and S Mburu and U Mrowietz and K Reich and E Remenyik and R{\o}nholt, {K M} and Sator, {P G} and M Schmitt-Egenolf and M Sikora and K Str{\"o}mer and O Sundnes and D Trigos and {Van Der Kraaij}, G and N Yawalkar and C Dressler",
note = "{\textcopyright} 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.",
year = "2021",
month = feb,
doi = "10.1111/jdv.16926",
language = "English",
volume = "35",
pages = "281--317",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations

AU - Nast, A

AU - Smith, C

AU - Spuls, P I

AU - Avila Valle, G

AU - Bata-Csörgö, Z

AU - Boonen, H

AU - De Jong, E

AU - Garcia-Doval, I

AU - Gisondi, P

AU - Kaur-Knudsen, D

AU - Mahil, S

AU - Mälkönen, T

AU - Maul, J T

AU - Mburu, S

AU - Mrowietz, U

AU - Reich, K

AU - Remenyik, E

AU - Rønholt, K M

AU - Sator, P G

AU - Schmitt-Egenolf, M

AU - Sikora, M

AU - Strömer, K

AU - Sundnes, O

AU - Trigos, D

AU - Van Der Kraaij, G

AU - Yawalkar, N

AU - Dressler, C

N1 - © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

PY - 2021/2

Y1 - 2021/2

N2 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

AB - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

KW - Humans

KW - Psoriasis/complications

U2 - 10.1111/jdv.16926

DO - 10.1111/jdv.16926

M3 - Other (editorial matter etc.)

C2 - 33547728

VL - 35

SP - 281

EP - 317

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 2

ER -